After a thousand calls, the two-vote system finally landed the boots!

Yesterday (January 6), the website of the State Health and Family Planning Commission released a regular press conference notice, showing that "the State Health and Family Planning Commission will hold a regular press conference in January 2017 at 10:00 a.m. on January 9, 2017 (Monday) in the press conference hall on the first floor of Building 2, Xizhimen Office Area, introduce the spirit of the 2017 Health and Family Planning Work Conference and interpret the" Implementation Opinions on the Implementation of the "Two-Invoice System" in Drug Procurement in Public Medical Institutions (Trial)." After a thousand calls, the two-vote system finally landed the boots!

At this point, despite the discussion around the world and even the lack of watchers, the announcement of the press conference officially announced that the two-vote document, which has been circulated on the Internet for a long time, has finally officially landed. Public information shows that up to now, 24 provinces and cities in China have expressed their views on the two-vote system, actively encouraging pilot cities for comprehensive reform of public hospitals to implement the "two-vote system", and Anhui and Hunan provinces have issued opinions on the implementation of the two-vote system. It is also clear that the two-vote system will be implemented in 2017. And a series of frequent high-level voices continue to send a message to the pharmaceutical industry. With the phased measure of the two-vote system as a breakthrough, the purge of the pharmaceutical circulation order will become the norm for a period of time in the future.

Gu Xin, a professor at the School of Government Management of Peking University, said in an interview with the media on this topic that the two-vote system will have a profound impact on China's pharmaceutical industry-after the implementation of the policy, thousands of pharmaceutical commercial companies whose main business is "scalping" will close down. The wave of mergers and acquisitions in the pharmaceutical business sector is surging.

More importantly, when facing medical terminals, especially public hospitals, Chinese-style CSO enterprises must no longer limit themselves to the roles of distributors, medical representatives and drug bugs. The accompanying business model of comprehensive medical services is very likely to become a new tide, and hospitals can integrate businesses other than the core of medical services, such as pharmacy operation and management, consumables and equipment procurement and management, information management, financing management, logistics management, logistics management, technology open services, academic support services, etc., are outsourced. In this way, the link between pharmaceutical companies and medical institutions is not just CSO, but a comprehensive hospital service company.